Stockwatch: A Brief History Of Asset Swaps
This article was originally published in Scrip
Executive Summary
Even with the proposed acquisition of Allergan Plc by Pfizer Inc., 2015 was not so much the year of life science M&A or even the bursting of the biotech bubble but the rise in the asset-swapping imperative. The jury is almost certainly still out for this development amongst big pharmaceutical companies so unlike the pharmaceutical mega-merger there is at least one reason why we may continue to see asset swap transactions in 2016.
You may also be interested in...
Stock Watch: Acadia And Amylyx Trial Failures Were No Shock
The overused phrase ‘pipeline in a product’ translates to ‘disappointment in a product’ when the number of indications in the pipeline contracts towards zero.
Stock Watch: COVID-19 Casts Long Shadow Over Pharma Sales
Social media-promoted vaccine hesitancy could have been a factor in the dip in established fourth-quarter vaccine sales with younger age groups targeted rather than seniors. Other drug categories may benefit from lifestyle changes prompted by the pandemic.
Stock Watch: Advanced Therapies Deliver Fourth-Quarter Flop
As drug pricing continues its ascent among hot button issues, the multi-million-dollar price tags for one-and-done advanced therapies, their justification and reimbursement all remain unaligned.